OBJECTIVE: The current rearrangement ratio of BRCA1 and BRCA2 genes is not known in the Turkish population. Rearrangements are not routinely investigated in many Turkish laboratories. This creates problems and contradictions between clinics. Therefore, the aim of this study was to evaluate the distribution and frequency of rearrangements in BRCA1 and BRCA2 genes in high-risk families and to clarify the limits of BRCA1 and BRCA2 testing in Turkey. MATERIALS AND METHODS: The study included 1809 patients at high risk of breast cancer or ovarian cancer. All patients were investigated for both small indels and rearrangements of BRCA genes using DNA sequencing and multiplex ligation-dependent probe amplification (MLPA) analysis. RESULTS: The overall frequency of rearrangements was 2% (25/1262). The frequency of rearrangements was 1.7% (18/1086) and 4% (9/206) in patients with breast cancer and ovarian cancer, respectively. The frequency of rearrangements was 3.7% (8/215) in patients with triple-negative breast cancer. The rearrangement rate was 7.7% (2/26) in patients with both breast and ovarian cancer. CONCLUSIONS: Rearrangements were found with high rates and were strongly associated with bilateral and triple-negative status of patients with breast cancer, which are signs of high risk for breast and ovarian cancer. Analysis of rearrangements should definitely be included in routine clinical practice in Turkey for high-risk families and also for improved cancer risk prediction for families.
OBJECTIVE: The current rearrangement ratio of BRCA1 and BRCA2 genes is not known in the Turkish population. Rearrangements are not routinely investigated in many Turkish laboratories. This creates problems and contradictions between clinics. Therefore, the aim of this study was to evaluate the distribution and frequency of rearrangements in BRCA1 and BRCA2 genes in high-risk families and to clarify the limits of BRCA1 and BRCA2 testing in Turkey. MATERIALS AND METHODS: The study included 1809 patients at high risk of breast cancer or ovarian cancer. All patients were investigated for both small indels and rearrangements of BRCA genes using DNA sequencing and multiplex ligation-dependent probe amplification (MLPA) analysis. RESULTS: The overall frequency of rearrangements was 2% (25/1262). The frequency of rearrangements was 1.7% (18/1086) and 4% (9/206) in patients with breast cancer and ovarian cancer, respectively. The frequency of rearrangements was 3.7% (8/215) in patients with triple-negative breast cancer. The rearrangement rate was 7.7% (2/26) in patients with both breast and ovarian cancer. CONCLUSIONS: Rearrangements were found with high rates and were strongly associated with bilateral and triple-negative status of patients with breast cancer, which are signs of high risk for breast and ovarian cancer. Analysis of rearrangements should definitely be included in routine clinical practice in Turkey for high-risk families and also for improved cancer risk prediction for families.
Entities:
Keywords:
BRCA1 and BRCA2 genes; High-risk breast and ovarian carcinoma; Turkish population; rearrangements
Authors: Ava Kwong; Jiawei Chen; Vivian Y Shin; John C W Ho; Fian B F Law; Chun Hang Au; Tsun-Leung Chan; Edmond S K Ma; James M Ford Journal: Cancer Genet Date: 2015-06-09
Authors: Maurizia Dalla Palma; Giuseppe Lombardi; Martin E Donach; Lucia Borgato; Fable Zustovich; Lara Furini; Maria O Nicoletto Journal: Am J Clin Oncol Date: 2011-06 Impact factor: 2.339
Authors: Sara Gutiérrez-Enríquez; Miguel de la Hoya; Cristina Martínez-Bouzas; Ana Sanchez de Abajo; Teresa Ramón y Cajal; Gemma Llort; Ignacio Blanco; Elena Beristain; Eduardo Díaz-Rubio; Carmen Alonso; María-Isabel Tejada; Trinidad Caldés; Orland Diez Journal: Breast Cancer Res Treat Date: 2006-10-25 Impact factor: 4.872
Authors: Brant C Hendrickson; Thaddeus Judkins; Benjamin D Ward; Kristilyn Eliason; Amie E Deffenbaugh; Lynn Anne Burbidge; Kristin Pyne; Benoît Leclair; Brian E Ward; Thomas Scholl Journal: Genes Chromosomes Cancer Date: 2005-07 Impact factor: 5.006
Authors: Esra Manguoğlu; Sefik Güran; Deniz Yamaç; Taner Colak; Mehmet Simşek; Mehmet Baykara; Mustafa Akaydın; Güven Lüleci Journal: Cancer Genet Cytogenet Date: 2010-12
Authors: Sumadee De Silva; Kamani Hemamala Tennekoon; Eric Hamilton Karunanayake; Indrani Amarasinghe; Preethika Angunawela Journal: BMC Res Notes Date: 2014-06-06
Authors: Petra Vasickova; Eva Machackova; Miroslava Lukesova; Jiri Damborsky; Ondrej Horky; Hana Pavlu; Jitka Kuklova; Veronika Kosinova; Marie Navratilova; Lenka Foretova Journal: BMC Med Genet Date: 2007-06-11 Impact factor: 2.103
Authors: Moon-Woo Seong; Sung Im Cho; Kyu Hyung Kim; Il Yong Chung; Eunyoung Kang; Jong Won Lee; Sue K Park; Min Hyuk Lee; Doo Ho Choi; Cha Kyong Yom; Woo-Chul Noh; Myung Chul Chang; Sung Sup Park; Sung-Won Kim Journal: BMC Cancer Date: 2014-09-01 Impact factor: 4.430